• Pomalidomide (CC-4047): Protocol Optimization for Myeloma Re

  2026-05-28

  Pomalidomide (CC-4047) is redefining experimental workflows in hematological malignancy research by offering targeted tumor microenvironment modulation and robust cytokine inhibition. This guide delivers step-by-step protocols, troubleshooting strategies, and actionable insights grounded in recent mutational landscape studies, uniquely positioning researchers to tackle multiple myeloma heterogeneity and drug resistance.

• Antipyrine in CNS Drug Discovery: Applied Workflows & BBB As

  2026-05-27

  Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) stands out as a validated reference for high-throughput blood-brain barrier (BBB) and pharmacokinetic studies, streamlining CNS drug discovery. This guide delivers actionable protocols, data-driven troubleshooting, and insights from the latest surrogate BBB model innovations.

• Pazopanib Hydrochloride: Applied Protocols in Cancer Researc

  2026-05-27

  Explore advanced, evidence-driven workflows for using Pazopanib Hydrochloride in cancer research, with a focus on in vitro and in vivo applications. Gain actionable troubleshooting tips and protocol optimizations that leverage this multi-target tyrosine kinase inhibitor’s unique profile.

• RG108 DNA Methyltransferase Inhibitor: Applied Epigenetic Wo

  2026-05-26

  RG108, a potent DNA methyltransferase inhibitor from APExBIO, empowers researchers with precise, non-covalent epigenetic gene regulation. Its unique workflow reliability and selective demethylation make it a preferred tool for tumor suppressor gene reactivation in advanced cancer research models.

• Cathepsin B Inhibitor CA-074: Technical Guide and Best Pract

  2026-05-26

  Cathepsin B inhibitor CA-074 (SKU A1926) addresses the need for selective, nanomolar-potency inhibition of cathepsin B in workflows investigating cancer metastasis, neurotoxicity, and immune modulation. This product should be prioritized where high selectivity and minimal off-target effects are crucial, but is not suitable for studies requiring broad-spectrum protease inhibition or long-term solution stability.

• Triggered Capture-and-Release Enhances LFA Sensitivity via R

  2026-05-25

  A recent study introduces a 'capture-and-release' strategy, termed AmpliFold, which significantly improves the sensitivity of lateral flow assays by enabling high-affinity rebinding and signal amplification. This approach leverages cleavable linkers and dual-affinity nanoparticles, offering a practical advance for point-of-care diagnostic sensitivity.

• Phosphoproteomic Remodeling in RCC Under Chronic Cabozantini

  2026-05-25

  This study dissects how renal cell carcinoma (RCC) cells adapt their phosphorylation networks and motility upon acute versus chronic Cabozantinib (XL184) treatment. Quantitative phosphoproteomics and functional assays reveal that chronic exposure leads to selective adhesion- and stress-related signaling adaptations, informing future research into resistance and targeted therapy strategies.

• Cy7 NHS Ester: Practical Guide for Near-Infrared Protein Lab

  2026-05-24

  Cy7 NHS ester addresses the challenge of labeling sensitive proteins and peptides for near-infrared fluorescent imaging by providing a highly water-soluble, sulfonated dye with minimal protein denaturation risk. Researchers should use this reagent when high water solubility and reduced fluorescence quenching are essential, but should avoid it for long-term solution storage or applications requiring extreme chemical stability.

• circ_0001944 Modulates FXR/TLR4 and Ferroptosis in NiONP Fib

  2026-05-23

  This study demonstrates that the circular RNA hsa_circ_0001944 mitigates nickel oxide nanoparticle-induced collagen deposition in hepatic stellate cells by regulating the FXR/TLR4 signaling pathway and ferroptosis. The findings highlight a novel RNA-mediated regulatory axis relevant for liver fibrosis research and suggest new mechanistic entry points for nanoparticle toxicity studies.

• Translating sEH/Nrf2 Insights: (S)-1-(3-fluoro...) in Bone R

  2026-05-22

  A thought-leadership exploration of how (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) advances mechanistic and translational research on the hepatic sEH–Nrf2–osteoclastogenesis axis, with strategic recommendations for experimentalists seeking high-impact, reproducible results in signaling pathway modulation, redox biology, and bone disease.

• Tubastatin A Mitigates Myocardial Injury via Pyroptosis and

  2026-05-22

  The referenced study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, alleviates post-resuscitation myocardial damage in a porcine cardiac arrest model by suppressing both GSDME-mediated pyroptosis and MLKL-mediated necroptosis. These findings provide mechanistic insight into cell death pathways in cardiac injury and suggest potential for HDAC6 inhibition in translational cardiovascular research.

• Gap19: Selective Connexin 43 Hemichannel Blocker for Neuropr

  2026-05-21

  Gap19 is a selective connexin 43 hemichannel blocker peptide that enables targeted inhibition of Cx43 hemichannels without affecting gap junction communication. It demonstrates potent neuroprotective activity in ischemic models and modulates inflammatory signaling via the Cx43/NF-κB pathway. This article consolidates mechanistic, benchmark, and workflow evidence for Gap19 as a research tool.

• Strategic Application of Methylprednisolone Sodium Succinate

  2026-05-21

  This thought-leadership article explores the mechanistic underpinnings and translational strategies surrounding Methylprednisolone Sodium Succinate, a synthetic corticosteroid, in advanced inflammation and immunology research. Integrating the latest evidence and workflow-driven insights, we provide actionable guidance for translational researchers aiming to optimize experimental reproducibility, apoptosis induction in tumor cells, and acute injury model outcomes. The discussion bridges bench and bedside, highlights competitive advantages, and offers a visionary outlook for the next generation of corticosteroid-enabled translational science.

• Targeting NUAK1/2 to Reduce Tau Ser356 Phosphorylation in Al

  2026-05-20

  This study reveals that phosphorylation of tau at Ser356, mediated by NUAK1, is closely associated with Alzheimer’s disease progression. It further demonstrates that selective NUAK1/2 inhibition with WZ4003 can reduce p-tau Ser356 in human brain slice cultures, highlighting a potential avenue for targeted therapeutic development.

• Anlotinib in IADSRCT: First Evidence for Multi-Target TKI Ef

  2026-05-20

  This case report presents the first documented use of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in treating intra-abdominal desmoplastic small round cell tumor (IADSRCT). The substantial reduction of metastatic lymph nodes after anlotinib administration highlights its translational potential for rare, aggressive sarcomas lacking standard targeted therapies.

14763 records 4/985 page Previous Next 12345 下5页 Last page